vs

Side-by-side financial comparison of Custom Truck One Source, Inc. (CTOS) and Sarepta Therapeutics, Inc. (SRPT). Click either name above to swap in a different company.

Custom Truck One Source, Inc. is the larger business by last-quarter revenue ($422.2M vs $369.6M, roughly 1.1× Sarepta Therapeutics, Inc.). Custom Truck One Source, Inc. runs the higher net margin — -4.2% vs -111.5%, a 107.3% gap on every dollar of revenue. On growth, Custom Truck One Source, Inc. posted the faster year-over-year revenue change (-8.5% vs -42.1%). Over the past eight quarters, Custom Truck One Source, Inc.'s revenue compounded faster (14.8% CAGR vs 1.4%).

Custom Truck One Source, Inc. is a leading provider of specialized heavy truck and equipment solutions in North America. It offers custom vehicle manufacturing, equipment sales and rentals, aftermarket parts, and maintenance services, serving core infrastructure, utility, construction, and energy industry segments.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

CTOS vs SRPT — Head-to-Head

Bigger by revenue
CTOS
CTOS
1.1× larger
CTOS
$422.2M
$369.6M
SRPT
Growing faster (revenue YoY)
CTOS
CTOS
+33.5% gap
CTOS
-8.5%
-42.1%
SRPT
Higher net margin
CTOS
CTOS
107.3% more per $
CTOS
-4.2%
-111.5%
SRPT
Faster 2-yr revenue CAGR
CTOS
CTOS
Annualised
CTOS
14.8%
1.4%
SRPT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CTOS
CTOS
SRPT
SRPT
Revenue
$422.2M
$369.6M
Net Profit
$-17.8M
$-412.2M
Gross Margin
20.3%
Operating Margin
2.9%
-111.4%
Net Margin
-4.2%
-111.5%
Revenue YoY
-8.5%
-42.1%
Net Profit YoY
-333.7%
-359.2%
EPS (diluted)
$-0.08
$-3.92

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTOS
CTOS
SRPT
SRPT
Q1 26
$422.2M
Q4 25
$387.3M
$369.6M
Q3 25
$359.9M
$370.0M
Q2 25
$392.2M
$513.1M
Q1 25
$307.1M
$611.5M
Q4 24
$398.3M
$638.2M
Q3 24
$337.5M
$429.8M
Q2 24
$320.6M
$360.5M
Net Profit
CTOS
CTOS
SRPT
SRPT
Q1 26
$-17.8M
Q4 25
$20.9M
$-412.2M
Q3 25
$-5.8M
$-50.6M
Q2 25
$-28.4M
$196.9M
Q1 25
$-17.8M
$-447.5M
Q4 24
$27.6M
$159.0M
Q3 24
$-17.4M
$33.6M
Q2 24
$-24.5M
$6.5M
Gross Margin
CTOS
CTOS
SRPT
SRPT
Q1 26
20.3%
Q4 25
31.8%
Q3 25
28.0%
59.3%
Q2 25
26.1%
70.3%
Q1 25
27.9%
77.5%
Q4 24
29.7%
Q3 24
27.2%
78.7%
Q2 24
27.8%
87.6%
Operating Margin
CTOS
CTOS
SRPT
SRPT
Q1 26
2.9%
Q4 25
13.4%
-111.4%
Q3 25
9.1%
-27.9%
Q2 25
7.1%
22.5%
Q1 25
4.0%
-49.1%
Q4 24
16.9%
25.3%
Q3 24
6.8%
5.2%
Q2 24
5.5%
-0.2%
Net Margin
CTOS
CTOS
SRPT
SRPT
Q1 26
-4.2%
Q4 25
5.4%
-111.5%
Q3 25
-1.6%
-13.7%
Q2 25
-7.2%
38.4%
Q1 25
-5.8%
-73.2%
Q4 24
6.9%
24.9%
Q3 24
-5.2%
7.8%
Q2 24
-7.6%
1.8%
EPS (diluted)
CTOS
CTOS
SRPT
SRPT
Q1 26
$-0.08
Q4 25
$0.10
$-3.92
Q3 25
$-0.03
$-0.50
Q2 25
$-0.13
$1.89
Q1 25
$-0.08
$-4.60
Q4 24
$0.11
$1.56
Q3 24
$-0.07
$0.34
Q2 24
$-0.10
$0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTOS
CTOS
SRPT
SRPT
Cash + ST InvestmentsLiquidity on hand
$6.3M
$939.6M
Total DebtLower is stronger
$25.9M
$829.0M
Stockholders' EquityBook value
$809.1M
$1.1B
Total Assets
$3.4B
$3.3B
Debt / EquityLower = less leverage
0.03×
0.73×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTOS
CTOS
SRPT
SRPT
Q1 26
$6.3M
Q4 25
$6.3M
$939.6M
Q3 25
$13.1M
$851.0M
Q2 25
$5.3M
$800.1M
Q1 25
$5.4M
$522.8M
Q4 24
$3.8M
$1.4B
Q3 24
$8.4M
$1.2B
Q2 24
$8.1M
$1.5B
Total Debt
CTOS
CTOS
SRPT
SRPT
Q1 26
$25.9M
Q4 25
$1.6B
$829.0M
Q3 25
$1.6B
$140.5M
Q2 25
$1.6B
Q1 25
$1.6B
Q4 24
$1.5B
$1.1B
Q3 24
$1.6B
$1.2B
Q2 24
$1.5B
$1.2B
Stockholders' Equity
CTOS
CTOS
SRPT
SRPT
Q1 26
$809.1M
Q4 25
$809.1M
$1.1B
Q3 25
$784.7M
$1.3B
Q2 25
$790.1M
$1.4B
Q1 25
$813.4M
$1.1B
Q4 24
$861.3M
$1.5B
Q3 24
$837.5M
$1.2B
Q2 24
$856.7M
$1.1B
Total Assets
CTOS
CTOS
SRPT
SRPT
Q1 26
$3.4B
Q4 25
$3.4B
$3.3B
Q3 25
$3.5B
$3.5B
Q2 25
$3.6B
$3.7B
Q1 25
$3.5B
$3.5B
Q4 24
$3.5B
$4.0B
Q3 24
$3.6B
$3.6B
Q2 24
$3.5B
$3.4B
Debt / Equity
CTOS
CTOS
SRPT
SRPT
Q1 26
0.03×
Q4 25
2.03×
0.73×
Q3 25
2.10×
0.11×
Q2 25
2.04×
Q1 25
1.97×
Q4 24
1.77×
0.74×
Q3 24
1.87×
1.01×
Q2 24
1.79×
1.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTOS
CTOS
SRPT
SRPT
Operating Cash FlowLast quarter
$131.2M
Free Cash FlowOCF − Capex
$127.6M
FCF MarginFCF / Revenue
34.5%
Capex IntensityCapex / Revenue
1.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-307.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTOS
CTOS
SRPT
SRPT
Q1 26
Q4 25
$47.3M
$131.2M
Q3 25
$81.5M
$-14.6M
Q2 25
$125.7M
$261.3M
Q1 25
$55.6M
$-583.4M
Q4 24
$82.1M
$92.0M
Q3 24
$16.5M
$-70.7M
Q2 24
$37.8M
$14.9M
Free Cash Flow
CTOS
CTOS
SRPT
SRPT
Q1 26
Q4 25
$127.6M
Q3 25
$-37.5M
Q2 25
$229.5M
Q1 25
$-627.1M
Q4 24
$54.0M
Q3 24
$-108.0M
Q2 24
$-14.2M
FCF Margin
CTOS
CTOS
SRPT
SRPT
Q1 26
Q4 25
34.5%
Q3 25
-10.1%
Q2 25
44.7%
Q1 25
-102.5%
Q4 24
8.5%
Q3 24
-25.1%
Q2 24
-3.9%
Capex Intensity
CTOS
CTOS
SRPT
SRPT
Q1 26
Q4 25
1.0%
Q3 25
6.2%
Q2 25
6.2%
Q1 25
7.1%
Q4 24
6.0%
Q3 24
8.7%
Q2 24
8.1%
Cash Conversion
CTOS
CTOS
SRPT
SRPT
Q1 26
Q4 25
2.27×
Q3 25
Q2 25
1.33×
Q1 25
Q4 24
2.98×
0.58×
Q3 24
-2.10×
Q2 24
2.31×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTOS
CTOS

Equipment sales$273.9M65%
Rental revenue$116.3M28%
Parts sales and services$32.1M8%

SRPT
SRPT

Pmo Products$202.5M55%
Elevidys$110.4M30%
Other$56.7M15%

Related Comparisons